^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) +
    serclutamab talirine (ABBV-321) (DNA replication inhibitor, EGFR-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

    Published date:
    11/30/2020
    Excerpt:
    The pre-clinical efficacy of combined treatments was evaluated in multiple patient-derived xenograft (PDX) models of TNBC….Navitoclax plus ABBV-321, an EGFR-targeted ADC that displays more effective wild-type EGFR-targeting, elicited more significant tumor growth inhibition and regressions in the two highest EGFR-expressing models evaluated.
    DOI:
    10.1186/s13058-020-01374-8